Catastrophic antiphospholipid syndrome - 20 years later

Area of Science:

• Rheumatology
• Immunology
• Pathobiology

Background:

• Catastrophic antiphospholipid syndrome (APS) is a life-threatening condition characterized by rapid, widespread organ damage.
• It involves clinical evidence of multiorgan involvement, small vessel occlusions, and antiphospholipid antibodies.
• Key mechanisms include thrombosis and systemic inflammatory response syndrome, often triggered by precipitating factors.

Purpose of the Study:

• To summarize the key features, pathobiology, and management of catastrophic APS.
• To highlight the diagnostic criteria and therapeutic approaches for this severe syndrome.
• To provide an overview of the outcomes, including mortality and relapse rates.

Main Methods:

• Review of clinical and histopathological findings in patients with catastrophic APS.
• Analysis of pathobiologic mechanisms, including thrombosis and inflammation.
• Summary of current treatment strategies and their efficacy.

Main Results:

• Catastrophic APS presents with acute multiorgan involvement and small vessel occlusions.
• Thrombosis and systemic inflammation are central to its pathogenesis.
• Standard treatments include anticoagulants, corticosteroids, IVIg, and plasma exchange.
• Mortality is approximately 30%, despite comprehensive therapy.
• Relapse rates are notably low.

Conclusions:

• Catastrophic APS is a severe thrombotic and inflammatory disorder requiring prompt, aggressive management.
• While treatment has improved outcomes, mortality remains a significant concern.
• The low rate of relapse suggests long-term disease control may be achievable with appropriate therapy.